NCT03390738 2021-05-03
Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy
The University of Hong Kong
Phase 2 Withdrawn
Clinical Trials
3 trialsNCT04231864 2020-10-26
Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer
University of California, San Francisco
Phase 2 Withdrawn
NCT00367718 2020-05-18
Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma
Johns Hopkins University
Phase 2 Withdrawn